Abu Dhabi based pharmaceutical manufacturer Neopharma has diversified into new segments with the launch of four new products to cater to the needs of the UAE as well enlarging exports market. The company, known for introducing new products in quick succession, is focusing on strengthening its antibiotic portfolio, with key anti-biotics such as coamoxyclav, clarithromycin and ciprofloxacin already in the market, the introduction of cefuroxime axetil and doxycycline will witness the company’s foray into the cephalosporins and tetracycline antibiotics segments.
NMC has donated life saving medicines amounting to Dh 1.3 million for the victims of Israeli aggression on Lebanon. Neopharma and NMC trading also donated 12 containers containing life saving medicines, analgesics, antibiotics, vaccines, baby-diapers, band –aids and other medical care items to the Relief Aid to Lebanon organized by DOHMS, Dubai recently and to Red Crescent, Abu Dhabi.
Dr. Ali Al Sayed Hussain, Director, Pharmaceutical Services Department, DOHMS, appreciated NMC’s immediate response and contribution towards the noble cause.
The Abu Dhabi based pharmaceutical producer, Neopharma, is all set to introduce 8 new brands in the domestic market. These products will further strengthen the company’s franchise in the antibiotics, analgesics and respiratory medicine segments. The introduction also marks Neopharma’s foray into the nutritional supplements market.
With these new products entering into the market, Neopharma’s total tally of offerings will increase to 42 products. Talking on this expanded product offerings, Dr. B R Shetty, Managing Director & CEO, remarked that the company’s ability to introduce new products in quick succession emerges from a well orchestrated cohesive effort and serves as an important competitive advantage.
The company has had an impressive start in the domestic market and is today known for its innovative range, quality formulations and competitive prices. With exports on full swing, the expanded product mix is all set to propel the company into the elite list of top pharmaceutical players in the region.